Author

L. Wessels

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

E. Bosdriesz· 2 shared W. Zwart· 2 shared A. Bhattacharya· 1 shared A. F. M. Altelaar· 1 shared A. J. R. Heck· 1 shared A. Jurgens· 1 shared A. M. Bergman· 1 shared A. Martinez-Marti· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Bosdriesz

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Lack of detectable neoantigen depletion in treatment-naive cancers

M. Slagter, L. Fanchi, M. M. van Buuren, A. Velds, G. Bounova, L. Wessels, T. Schumacher

This study investigates neoantigen depletion in treatment-naive human tumors using two novel methodologies, finding no statistically significant evidence for depletion after controlling for confounding factors.

bioRxiv · Jun 21, 2023 · PreprintCancer Biology

MYC promotes immune-suppression in TNBC via inhibition of IFN signaling

D. Zimmerli, C. S. Brambillasca, F. Talens, J. Bhin, A. Bhattacharya, S. E. P. Joosten, A. Moises da Silva, M. D. Wellenstein, K. Kersten, M. de Boo, M. Roorda, L. Henneman, R. de Bruijn, S. Annunziato, E. van der Burg, , J. Jonkers

This study shows MYC overexpression in TNBC reduces immune cell infiltration and interferon signaling, contributing to immune evasion and poor response to immunotherapy.

bioRxiv · Feb 24, 2021 · PreprintCancer Biology

Human Prostate Cancer-Associated Macrophage Subtypes with Prognostic Potential Revealed by Single-cell Transcriptomics

J. C. Siefert, B. Cioni, M. J. Muraro, M. Alshalalfa, J. Vivie, H. van der Poel, F. Y. Feng, L. Wessels, W. Zwart, A. M. Bergman

The paper identifies three macrophage subtypes in human prostate cancer using single-cell transcriptomics and develops a gene signature linked to patient survival.

bioRxiv · Jun 19, 2020Immunology

Multiple Low Dose therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

J. M. Fernandes Neto, E. Nadal, S. N. Ooft, E. Bosdriesz, L. Farre, C. McLean, S. Klarenbeek, A. Jurgens, H. Hagen, L. Wang, E. Felip, A. Martinez-Marti, E. Voest, L. Wessels, O. van Tellingen, , R. Bernards

This paper shows that using multiple low doses of drugs targeting different components of a signaling pathway can effectively treat EGFR inhibitor-resistant NSCLC without resistance development.

bioRxiv · Oct 29, 2019Cancer Biology

A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells

A. Ressa, E. Bosdriesz, J. de Ligt, S. Mainardi, G. Maddalo, A. Prahallad, M. Jager, L. de la Fonteijne, M. Fitzpatrick, S. Groten, A. F. M. Altelaar, R. R. Bernards, E. Cuppen, L. Wessels, A. J. R. Heck

The paper investigates molecular responses to BRAF and EGFR inhibition in colorectal cancer cells, revealing metabolic shifts and MAPK pathway reactivation.

bioRxiv · Sep 27, 2017Cancer Biology